Benzinga · Jul 16, 2026
Immuron Sees Prelim FY2026 Sales $5.462M
Immuron (NASDAQ:IMRN) sees Prelim FY2026 sales of $5.462 million.
IM
NASDAQ · IMRN
Immuron Limited
Healthcare · Biotechnology
$1.10
Down-$0.03 (-2.65%)
Updated Aug 15, 2026, 4:01 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 6.09M
- P/E ratio
- -1.74
- Dividend yield
- 0.00%
- 52-week range
- $0.70 – $1.60
- Volume
- 33.3K
- Avg. volume
- 545.45K
Price performance
IMRN price history
1M range · 21 trading sessions · Daily adjusted prices
IMRN closed at $1.10 after 21 trading sessions, down 9.09% for the selected period.
- Last close
- $1.10
- Period change
- -9.09%
- Period low
- $1.03
- Period high
- $1.22
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $1.13 | $1.14 | $1.0301 | $1.10 | 33.3K |
| Aug 13, 2026 | $1.10 | $1.16 | $1.09 | $1.13 | 11.12K |
| Aug 12, 2026 | $1.09 | $1.13 | $1.09 | $1.1005 | 7.01K |
| Aug 11, 2026 | $1.11 | $1.135 | $1.0924 | $1.10 | 14.7K |
| Aug 10, 2026 | $1.09 | $1.15 | $1.0401 | $1.10 | 23.33K |
| Aug 7, 2026 | $1.0651 | $1.0651 | $1.02 | $1.031 | 9.25K |
| Aug 6, 2026 | $1.09 | $1.10 | $1.0353 | $1.10 | 12.15K |
| Aug 5, 2026 | $1.08 | $1.1538 | $1.05 | $1.10 | 7.24K |
| Aug 4, 2026 | $1.03 | $1.09 | $1.03 | $1.08 | 11.16K |
| Aug 3, 2026 | $1.13 | $1.13 | $1.03 | $1.06 | 44.47K |
| Jul 31, 2026 | $1.135 | $1.14 | $1.08 | $1.09 | 11.26K |
| Jul 30, 2026 | $1.08 | $1.14 | $1.0301 | $1.11 | 21.51K |
| Jul 29, 2026 | $1.0701 | $1.1199 | $1.04 | $1.095 | 32.63K |
| Jul 28, 2026 | $1.09 | $1.11 | $1.0639 | $1.095 | 6.85K |
| Jul 27, 2026 | $1.12 | $1.1202 | $1.06 | $1.06 | 36.17K |
| Jul 24, 2026 | $1.17 | $1.17 | $1.08 | $1.11 | 19.2K |
| Jul 23, 2026 | $1.11 | $1.1847 | $1.09 | $1.17 | 34.78K |
| Jul 22, 2026 | $1.22 | $1.22 | $1.11 | $1.13 | 47.67K |
| Jul 21, 2026 | $1.15 | $1.2299 | $1.11 | $1.22 | 36.3K |
| Jul 20, 2026 | $1.21 | $1.21 | $1.11 | $1.13 | 54.83K |
| Jul 17, 2026 | $1.12 | $1.22 | $1.0812 | $1.21 | 24.68K |
Latest IMRN news
The latest Smart Investors Daily articles mentioning IMRN.
Stock researchCompany · Overview
IMRN research
Overview
Company profile and research snapshot.
Company profile
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 18, 2017 | H.C. Wainwright | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Jul 6, 2026
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering StrategyImmuron is seeking a partner to support clinical development through regulatory approval and commercializationImmuron has U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) applicationIND 32095 is Immuron’s Investigational new drug (IND) application for clinical development of IMM-529 as a product to specifically prevent or treat Clostridioides difficile infection (CDI) MEL
Benzinga · Jul 6, 2026
Immuron Hires Pullan To Find Partner For Gut Infection Drug, Seeks Strategic Partner For FDA-Cleared IMM-529 Trial
Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to announce that it has engaged Pullan Consulting to provide business development services to assist in securing a strategic partnership for IMM-529.Pullan Consulting
Benzinga · Feb 25, 2026
Immuron H1 EPS $(0.01), Same YoY, Sales $4.184M Up From $3.994M YoY
Immuron (NASDAQ:IMRN) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $4.184 million in sales this quarter. This is a 4.76 percent increase over
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
